The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma (Q37567174)
Jump to navigation
Jump to search
scientific article published on 05 January 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma |
scientific article published on 05 January 2017 |
Statements
1 reference
The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma (English)
1 reference
Giovanni Luca Gravina
1 reference
Francesco Marampon
1 reference
Alessandro Colapietro
1 reference
Simona Delle Monache
1 reference
Roberta Sferra
1 reference
Flora Vitale
1 reference
Peter J Richardson
1 reference
Lee Patient
1 reference
Stephen Burbidge
1 reference
Claudio Festuccia
1 reference
5 January 2017
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference